Review
References
| Ahmed A, Paris MM, Trujillo M, Hickey SM, Wubbel L, Shelton SL, McCracken GH Jr (1997). Once-daily gentamicin therapy for experimental Escherichia coli meningitis. Antimicrob. Agents Chemother. 7(41):49–53. | ||||
|
Al-Mazrou YY, Al-Jeffri MH, Abdalla MN, Elgizouli SA, Mishskas AA (2004). Changes in epidemiological pattern of Meningococcal disease in Saudi Arabia. Does it constitute a new challenge for prevention and control? Saudi Med. J. 25(10):1410-1413. PubMed |
||||
|
Andes DR, Craig WA (1999). Pharmacokinetics and pharmacodynamics of antibiotics in meningitis. Infect. Dis. Clin. North Am. 13:595–618. Crossref |
||||
|
Aronin SI (2000). Bacterial meningitis: principles and practical aspects of therapy. Curr. Infect. Dis. Rep. 2:337–344. Crossref |
||||
|
Bamberger DM (2010). Diagnosis, initial management, and prevention of meningitis. Am. Fam. Physician 82:1491-1498. PubMed |
||||
| Bartt R (2012). Acute bacterial and viral meningitis. Infect. Dis. 18(6):1255-1270. | ||||
|
Bleck TP (2013). Bacterial meningitis and other nonviral infections of the nervous system. Crit. Care Clin. 29:975-987. Crossref |
||||
|
Brouwer MC, Thwaites GE, Tunkel AR, van de Beek D (2012). Dilemmas in the diagnosis of acute community-acquired bacterial meningitis. Lancet 380:1684. Crossref |
||||
|
Brouwer MC, Tunkel AR, van de Beek D (2010). Epidemiology, diagnosis, and antimicrobial treatment of acute bacterial meningitis. Clin. Microbiol. Rev. 23:467-942. Crossref |
||||
|
CDC, Centers for Diseases Control and Prevention (2011). Epidemiology of Meningitis Caused by Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenza. |
||||
|
Chavez-Bueno S, McCracken GH Jr (2005). Bacterial meningitis in children. Pediatr. Clin. North Am. 52:795–810. Crossref |
||||
|
Choi C (1992). Bacterial meningitis. Clin. Geriatric Med. 8(4):889–902. PubMed |
||||
|
Chowdhury MH, Tunkel AR (2000). Antibacterial agents in infections of the central nervous system. Infect. Dis. Clin. North Am. 14:391–408. Crossref |
||||
|
Darouiche R, Perkins B, Musher D, Hamill R, Tsai S (1990). Levels of rifampin and ciprofloxacin in nasal secretions: correlation with MIC90 and eradication of nasopharyngeal carriage of bacteria. J. Infect. Dis. 162:1124-1127. Crossref |
||||
|
European Medicines Agency (2012). Prevenar: pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed). |
||||
| Fraser DW, Geil CC, Feldman RA (1947). Bacterial meningitis in Bernailillo County, New Mexico: a comparison with three other American populations. Am. J. Epidemiol. 100(1):29–34. | ||||
|
Geiseler PJ, Nelson KE, Levin S, Reddi KT, Moses VK (1980). Community-acquired purulent meningitis: a review of 1316 cases during the antibiotic era 1954–1976. Rev. Infect. Dis. 2(5):725–745. Crossref |
||||
|
Hall LMC, Duke B, Urwin G (1995). An approach to the identification of the pathogens of bacterial meningitis by the polymerase chain reaction. Eur. J. Clin. Infect. Dis. 14(12):1090-1094. Crossref |
||||
|
Kasiakou SK, Sermaides GJ, Michalopoulos A, Soteriades ES, Falagas ME (2005). Continuous versus intermittent intravenous administration of antibiotics: a meta-analysis of randomized controlled trials. Lancet Infect. Dis. 5:581–589. Crossref |
||||
|
Kim YS, Liu Q, Chow LL, TÙ†uber MG (1997). Trovafloxacin in treatment of rabbits with experimental meningitis caused by high-level penicillin-resistant Streptococcus pneumoniae. Antimicrob. Agents Chemother. 41:1186–1189. PubMed |
||||
|
Lieberman JM, Greenberg DP, Ward JI (1990). Prevention of bacterial meningitis. Vaccines and chemoprophylaxis. Infect. Dis. Clin. North Am. 4:703-729. PubMed |
||||
| Loring KE (2004). CNS infections. In: Tintinalli JE, Kelen GD, Stapczynski JS (Eds.), Emergency medicine: a comprehensive study guide, 6th edition. McGraw-Hill, New York. pp. 1431–1437. | ||||
|
Lutsar I, Ahmed A, Friedland IR, Trujillo M, Wubbel L, Olsen K, McCracken GH Jr (1997). Pharmacodynamics and bactericidal activity of ceftriaxone therapy in experimental cephalosporin-resistant pneumococca meningitis. Antimicrob. Agents Chemother. 41:2414–2417. PubMed |
||||
|
Lutsar I, McCracken GH Jr, Friedland IR (1998). Antibiotic pharma-codynamics in cerebrospinal fluid. Clin Infect Dis. 27:1117–1129. Crossref |
||||
|
Mace SE (2008). Acute Bacterial Meningitis. Emerg. Med. Clin. N. Am. 38:281–317. Crossref |
||||
|
McCracken G (2000). Pharmacodynamics of gatifloxacin in experimental models of pneumococcal meningitis. Clin. Infect. Dis. 31(Suppl 2):S45–50. Crossref |
||||
|
McIntyre PB, O'Brien KL, Greenwood B, van de Beek D (2012) .Effect of vaccines on bacterial meningitis worldwide. Lancet 380:1703–1711. Crossref |
||||
|
Seppa N (2011). Vaccinations cut cases nearly one-third over past decade. Science News. Bacterial Meningitis Rates Fall. Crossref |
||||
|
Nau R, SÙrgel F, Eiffert H (2010). Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections. Clin. Microbiol. Rev. 223:858. Crossref |
||||
|
Porto I (2012). Acute Bacterial Meningitis.US Pharmacist. Accessed Feb.2013, |
||||
|
Rodriguez-Cerrato V, McCoid CC, Michelow IC, Ghaffar F, Jafri HS, Hardy RD, Patel C, Olsen K, McCracken GH Jr (2001). Pharmacodynamics and bactericidal activity of moxifloxacin in experimental Escherichia coli meningitis. Antimicrob. Agents Chemother. 45:3092–3097. Crossref |
||||
|
Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes JM (2001). Meningococcal Disease. N. Engl. J. Med. 344:1378-1388. Crossref |
||||
|
Schaad UB, Abdus Salam M, Aujard Y, Dagan R, Green SD, Peltola H, Rubio TT, Smith AL, Adam D (1995). Use of fluoroquinolones in pediatrics: consensus report of an International Society of Chemotherapy commission. Pediatr. Infect. Dis. J. 14:1-9. Crossref |
||||
|
Schutze GE, Mason EO Jr, Barson WJ, Kim KS, Wald ER, Givner LB, Tan TQ, Bradley JS, Yogev R, Kaplan SL (2002). Invasive pneumococcal infections in children with asplenia. Pediatr. Infect. Dis. J. 21:278–282. Crossref |
||||
| Seehusen DA, Reeves MM, Fomin DA (2003). Cerebrospinal fluid analysis "and remove "15:" and replace 1109 by "1108". Am. Fam. Physician 15:68(6):1103-1109. | ||||
|
Sinner SW, Tunkel AR (2004). Antimicrobial agents in the treatment of bacterial meningitis. Infect. Dis. Clin. North Am. 1:581–602. Crossref |
||||
|
Tang LM, Chen ST, HSU WC, LYU RK (1999). Acute bacterial meningitis in adults: a hospital-based epidemiology study. Q. J. Med. 92:719-725. Crossref |
||||
|
Thigpen MC, Whitney CG, Messonnier NE, Zell ER, Stat M, Lynfield R, Hadler JL, Harrison LH, Farley MM, Arthur Reingold A, Nancy M, Bennett NM, Craig AS, Schaffner W, Thomas A, Melissa M, Lewis MM, Elaine Scallan E, Schuchat A (2011). Bacterial meningitis in the United States, 1998-2007. N. Engl. J. Med. 364:2016-2025. Crossref |
||||
|
Tunkel AR, Hartman BJ, Kaplan SL, Kaufman BA, Karen L, Roos KL, Scheld WM, Whitley RJ (2004). Practice guidelines for the management of bacterial meningitis. Clin. Infect. Dis. 39:1267-1284. Crossref |
||||
| Tunkel AR, van de Beek D, Scheld MW (2009). Acute meningitis. In: Mandell GL, Bennett JE, Dolin R (Eds.), Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases, 7th ed., Churchill Livingstone Elsevier, Philadelphia. pp. 1189-1229. | ||||
|
Van de Beek D, Brouwer MC, Thwaites GE, Tunkel AR (2012). Advances in treatment of bacterial meningitis. Lancet 380:1693-1702. Crossref |
||||
|
Van de Beek D, de Gans J, Spanjaard L, Weisfelt M, Reitsma JB, Vermeulen MD (2004). Clinical features and prognostic factors in adults with bacterial meningitis. N. Engl. J. Med. 351:1849-1859. Crossref |
||||
|
World Health Organization (WHO). 2010. Changing epidemiology of pneumococcal serotypes after introduction of conjugate vaccine: July 2010 report. Wkly Epidemiol. Rec. 85:425–436. PubMed |
||||
Copyright © 2024 Author(s) retain the copyright of this article.
This article is published under the terms of the Creative Commons Attribution License 4.0
